EHA 2021 | Cardiac AEs in patients treated with ibrutinib
Mazyar Shadman
• 25 May 2021
Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discussess cardiovascular adverse events that occur in patients receiving BTK inhibitors, in particular those receiving ibrutinib. Dr Shadman reports that in the Phase II BGB-3111-215 trial (NCT04116437) of zanubrutinib for patients with B-cell malignancies and ibrutinib or acalabrutinib intolerance, the majority of patients did not have recurrence of hypertension or atrial fibrillation. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
